Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies-Reference-Cited by-同舟云学术

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

Published:2021-04-27 Issue:11 Volume:35 Page:3201-3211
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Furman Richard R.,Byrd John C.,Owen Roger G.,O’Brien Susan M.,Brown Jennifer R.^ORCID,Hillmen Peter,Stephens Deborah M.,Chernyukhin Nataliya,Lezhava Tamara,Hamdy Ahmed M.,Izumi Raquel,Patel Priti,Baek Marshall,Christian Beth,Dyer Martin J. S.^ORCID,Streetly Matthew J.,Sun Clare^ORCID,Rule Simon^ORCID,Wang Michael^ORCID,Ghia Paolo^ORCID,Jurczak Wojciech^ORCID,Pagel John M.^ORCID,Sharman Jeff P.

Funder

Acerta Pharma, a member of the AstraZeneca Group

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01252-y.pdf

Reference41 articles.

1. Vitale C, Burger JA. Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opin Pharmacother. 2016;17:1077–89.

2. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.

3. Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartzberg PL. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev. 2009;228:93–114.